The efficacy of homoharringtonine in pediatric acute myeloid leukemia: findings from the Chinese Children's Leukemia Group-AML 2015 Study
Samanta Catueno,Fadi G. Haddad,Branko Cuglievan
DOI: https://doi.org/10.21037/tp-23-536
2024-03-04
Translational Pediatrics
Abstract:Samanta Catueno 1^ , Fadi G. Haddad 2^ , Branko Cuglievan 1^ 1 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA ^ ORCID: Samanta Catueno, 0000-0002-0072-8603; Fadi G. Haddad, 0000-0002-9702-8485; Branko Cuglievan, 0000-0002-6917-2244. Comment on: Li J, Gao J, Liu A, et al . Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study. J Clin Oncol 2023;41:4881-92. Keywords: Homoharringtonine (HHT); leukemia; myeloid; maintenance Submitted Nov 01, 2023. Accepted for publication Jan 23, 2024. Published online Feb 23, 2024. doi: 10.21037/tp-23-536 Acute myeloid leukemia (AML) is a complex disease accounting for 15% to 20% of pediatric leukemia cases (1). Previous research has reported event-free survival (EFS) rates ranging from 53% to 63% and overall survival (OS) rates ranging from 63% to 74% in pediatric AML (2). Existing challenges in AML treatment encompass issues such as resistance to chemotherapy, therapy-related toxicity, the influence of infrequent molecular signatures and epigenetic mutations, challenges in recruiting patients for clinical trials, and delays in accessing treatment protocols designed for adults. Strategies to enhance this situation involve refining risk stratification through the use of more precise diagnostic tools like next-generation sequencing (NGS), creating targeted therapies to reduce the toxicity associated with conventional chemotherapy, and adjusting the age criteria for enrollment in adult trials (3-6). The Chinese Children's Leukemia Group-AML 2015 study, led by Jing Li, evaluated the effectiveness and safety of different treatment protocols for pediatric AML (7). Notably, this comprehensive, multicenter, open-label study spanning 35 centers across China explored the use of two specific treatments: homoharringtonine (HHT also known as omacetaxine), commonly used in adult AML in China; and all-trans retinoic acid (ATRA), known for its efficacy in treating acute promyelocytic leukemia. This study sought to clarify whether HHT-based induction therapy is safe and effective in pediatric AML and whether ATRA-based maintenance therapy is effective in patients with non-acute promyelocytic leukemia AML. This study is intriguing because it proposes alternative therapeutic approaches, such as the use of HHT, the use of etoposide in induction and the use of maintenance, that deviate from the established standard of care within the Children's Oncology Group protocols (AAML1831). In this study, children with newly diagnosed AML were randomly assigned to either an HHT-based (H-arm) or an etoposide-based (E-arm) induction regimen. The first phase (Induction I) involved the administration of VP-16 (etoposide, 100 mg/m 2 daily) or HHT (3 mg/m 2 daily) on days 1 to 5. Additionally, daunorubicin was given at a dose of 40 mg/m 2 daily on days 1, 3, and 5, and cytarabine was administered at a dosage of 100 mg/m 2 every 12 hours on days 1 to 7. For the induction II phase (E arm, idarubicin plus cytarabine plus etoposide; H arm, idarubicin plus cytarabine plus HHT), idarubicin was administered once daily at a dose of 10 mg/m 2 on days 1, 3, and 5, substituting daunorubicin. Following induction therapy, all patients received 3 courses of consolidation therapy, which included various regimens: mitoxantrone plus cytarabine, HHT plus cytarabine, and cytarabine plus L-asparaginase. High-risk patients ineligible for hematopoietic stem cell transplantation received an additional course of HHT plus cytarabine (7). For maintenance therapy, patients who did not undergo hematopoietic stem cell transplantation were randomly assigned to ATRA-based (AT-arm) or cytarabine-based (AC-arm) therapy for approximately 1 year. In the AT arm, therapy consisted of daily oral doses of ATRA (20–30 mg/m 2 ) for the first 2 weeks and daily oral 6-mercaptopurine (50 mg/m 2 ) for the following 10 weeks. In the AC arm, therapy consisted of intravenous cytarabine (40 mg/m 2 ) administered daily on days 1 to 4 every 4 weeks and oral 6-mercaptopurine (50 mg/m 2 ) given once daily throughout the entire maintenance period. Each cycle lasted 12 weeks, and patients completed four cycles. The primary endpoint of the study was the complete remission rate following induction therapy, and the secondary endpoints were the OS and EFS rates. Importantly, the study was initially designed as a multicenter, randomized, controlled trial, but it was changed to a multicenter, prospective, observational clinical trial due to an unexpected, 6-month HHT shortage. Consequ -Abstract Truncated-
pediatrics